IL318657A - Intranasal administration of NGF for the treatment of sensorineural hearing loss - Google Patents

Intranasal administration of NGF for the treatment of sensorineural hearing loss

Info

Publication number
IL318657A
IL318657A IL318657A IL31865725A IL318657A IL 318657 A IL318657 A IL 318657A IL 318657 A IL318657 A IL 318657A IL 31865725 A IL31865725 A IL 31865725A IL 318657 A IL318657 A IL 318657A
Authority
IL
Israel
Prior art keywords
ngf
treatment
hearing loss
intranasal administration
sensorineural hearing
Prior art date
Application number
IL318657A
Other languages
English (en)
Hebrew (he)
Inventor
Vanessa Castelli
Andrea Aramini
Laura Brandolini
Pasquale Cocchiaro
Tiziana Romeo
Nicola Detta
Lucia Apparente
Simone Mattioli
Franca Cattani
Flavio Mantelli
Marcello Allegretti
Original Assignee
Dompe Farm Spa
Vanessa Castelli
Andrea Aramini
Laura Brandolini
Pasquale Cocchiaro
Tiziana Romeo
Nicola Detta
Lucia Apparente
Simone Mattioli
Franca Cattani
Flavio Mantelli
Marcello Allegretti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Farm Spa, Vanessa Castelli, Andrea Aramini, Laura Brandolini, Pasquale Cocchiaro, Tiziana Romeo, Nicola Detta, Lucia Apparente, Simone Mattioli, Franca Cattani, Flavio Mantelli, Marcello Allegretti filed Critical Dompe Farm Spa
Publication of IL318657A publication Critical patent/IL318657A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
IL318657A 2022-08-05 2023-08-04 Intranasal administration of NGF for the treatment of sensorineural hearing loss IL318657A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22188990.0A EP4316505A1 (en) 2022-08-05 2022-08-05 Intranasal administration of ngf for the treatment of sensorineural hearing loss
PCT/EP2023/071698 WO2024028487A1 (en) 2022-08-05 2023-08-04 Intranasal administration of ngf for the treatment of sensorineural hearing loss

Publications (1)

Publication Number Publication Date
IL318657A true IL318657A (en) 2025-03-01

Family

ID=82846594

Family Applications (1)

Application Number Title Priority Date Filing Date
IL318657A IL318657A (en) 2022-08-05 2023-08-04 Intranasal administration of NGF for the treatment of sensorineural hearing loss

Country Status (7)

Country Link
EP (2) EP4316505A1 (https=)
JP (1) JP2025525989A (https=)
CN (1) CN119836297A (https=)
AU (1) AU2023317864A1 (https=)
CA (1) CA3263975A1 (https=)
IL (1) IL318657A (https=)
WO (1) WO2024028487A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4659759A1 (en) * 2024-06-04 2025-12-10 Dompé farmaceutici SpA Administration of ngf for the treatment of niemann-pick type c disease
WO2026022244A1 (en) 2024-07-23 2026-01-29 Chiesi Farmaceutici S.P.A. A polypeptide for use in the therapeutic management of acute ischaemic stroke

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2213861T3 (es) 1998-10-09 2004-09-01 Scil Proteins Gmbh Procedimiento de obtencion de ngf-beta activa.
ITRM20110390A1 (it) * 2011-07-21 2013-01-22 Eramo Alessandra D Prodotto per stimolare la produzione endogena di mediatori dell'infiammazione.
CN104203264B (zh) 2011-12-19 2018-08-28 瓦克化学有限公司 新型proNGF突变体及其在生产β-NGF中的用途
WO2017120465A1 (en) * 2016-01-06 2017-07-13 Massachusetts Eye And Ear Infirmary Treating cochlear synaptopathy
WO2018140792A2 (en) * 2017-01-27 2018-08-02 Otonomy, Inc. Neurotrophin mutants for treating hearing loss and other otic disorders
EP3406259A1 (en) * 2017-05-24 2018-11-28 Dompé farmaceutici S.p.A. Neurotrophins for use in the treatment of hearing loss
MA52351A (fr) 2018-04-27 2021-05-26 Chiesi Farm Spa Production du facteur de croissance nerveuse (ngf) et de mutéines de celui-ci
CN114829384B (zh) * 2020-11-19 2023-12-12 舒泰神（北京）生物制药股份有限公司 长效神经生长因子多肽及其用途

Also Published As

Publication number Publication date
CN119836297A (zh) 2025-04-15
EP4316505A1 (en) 2024-02-07
EP4565255A1 (en) 2025-06-11
CA3263975A1 (en) 2024-02-08
AU2023317864A1 (en) 2025-02-13
WO2024028487A1 (en) 2024-02-08
JP2025525989A (ja) 2025-08-07

Similar Documents

Publication Publication Date Title
IL318657A (en) Intranasal administration of NGF for the treatment of sensorineural hearing loss
CA203658S (en) Hearing aid
CA204747S (en) Hearing aid
CA198230S (en) Hearing aid
CA215228S (en) Set of earbuds
CA222948S (en) Pair of earphones
CA217476S (en) Speaker
IL318653A (en) Intranasal administration of BDNF for the treatment of sensorineural hearing loss
EP4125847A4 (en) ENTERAL AEROBIZATION THERAPY
CA218765S (en) Speaker
HK40122674A (en) Intranasal administration of ngf for the treatment of sensorineural hearing loss
IL315627A (en) Azasterone for the treatment of sudden sensorineural hearing loss
CA217747S (en) Hearing aid
HK40117061A (en) Azasetron for the treatment of sudden sensorineural hearing loss
CA221467S (en) Part of earphone
GB202303035D0 (en) Hearing aid
GB202202328D0 (en) Hearing aid
CA213269S (en) Pair of earphones
GB2626167B (en) Audio therapy
CA231305S (en) Speaker
CA231291S (en) Speaker
CA227164S (en) Speaker
CA225566S (en) Speaker
CA226520S (en) Speaker
CA223754S (en) Speaker